|
US2940998A
(en)
*
|
1953-10-15 |
1960-06-14 |
Ajinomoto Kk |
Process for resolution of racemic glutamic acid and salts thereof
|
|
GB919491A
(en)
*
|
1958-12-23 |
1963-02-27 |
Ici Ltd |
Pharmaceutical compositions
|
|
US4026897A
(en)
*
|
1974-01-31 |
1977-05-31 |
Otsuka Pharmaceutical Company |
5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
|
|
US3980637A
(en)
*
|
1975-03-17 |
1976-09-14 |
Bristol-Myers Company |
Production of amoxicillin
|
|
US4556654A
(en)
*
|
1983-06-28 |
1985-12-03 |
Warner-Lambert Company |
Antimicrobial substituted anthra[1,9-cd]pyrazol-6(2H)-ones
|
|
DE3403329A1
(de)
*
|
1984-02-01 |
1985-08-01 |
Horst Dr. 4019 Monheim Zerbe |
Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
|
|
FR2623810B2
(fr)
*
|
1987-02-17 |
1992-01-24 |
Sanofi Sa |
Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
|
|
US5158777A
(en)
*
|
1990-02-16 |
1992-10-27 |
E. R. Squibb & Sons, Inc. |
Captopril formulation providing increased duration of activity
|
|
CA2068402C
(en)
*
|
1991-06-14 |
1998-09-22 |
Michael R. Hoy |
Taste mask coatings for preparation of chewable pharmaceutical tablets
|
|
US5753652A
(en)
*
|
1991-07-03 |
1998-05-19 |
Novartis Corporation |
Antiretroviral hydrazine derivatives
|
|
CA2103932A1
(en)
*
|
1992-11-05 |
1994-05-06 |
Ramesh N. Patel |
Stereoselective reduction of ketones
|
|
US5461067A
(en)
*
|
1993-02-25 |
1995-10-24 |
Abbott Laboratories |
Retroviral protease inhibiting compounds
|
|
US5428048A
(en)
*
|
1993-11-08 |
1995-06-27 |
American Home Products Corporation |
Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents
|
|
GB9407386D0
(en)
*
|
1994-04-14 |
1994-06-08 |
Smithkline Beecham Plc |
Pharmaceutical formulation
|
|
UA49803C2
(uk)
*
|
1994-06-03 |
2002-10-15 |
Дж.Д. Сьорль Енд Ко |
Спосіб лікування ретровірусних інфекцій
|
|
TW483763B
(en)
*
|
1994-09-02 |
2002-04-21 |
Astra Ab |
Pharmaceutical composition comprising of ramipril and dihydropyridine compound
|
|
JP3529904B2
(ja)
*
|
1995-06-19 |
2004-05-24 |
鐘淵化学工業株式会社 |
光学活性１−ハロ−３−アミノ−４−フェニル−２−ブタノール誘導体の製造法
|
|
US6037157A
(en)
*
|
1995-06-29 |
2000-03-14 |
Abbott Laboratories |
Method for improving pharmacokinetics
|
|
US5750493A
(en)
*
|
1995-08-30 |
1998-05-12 |
Raymond F. Schinazi |
Method to improve the biological and antiviral activity of protease inhibitors
|
|
US5767316A
(en)
*
|
1995-11-17 |
1998-06-16 |
Ajinomoto Co., Inc. |
Process for producing 3-amino-2-oxo-1-halogenopropane derivatives
|
|
US5849911A
(en)
*
|
1996-04-22 |
1998-12-15 |
Novartis Finance Corporation |
Antivirally active heterocyclic azahexane derivatives
|
|
US6087383A
(en)
*
|
1998-01-20 |
2000-07-11 |
Bristol-Myers Squibb Company |
Bisulfate salt of HIV protease inhibitor
|
|
ATE250024T1
(de)
*
|
1999-01-21 |
2003-10-15 |
Kaneka Corp |
Methode zur reinigung und abtrennung von (2s,3s)- oder (2r,3s)-halohydrinderivaten
|
|
US6344572B1
(en)
*
|
1999-01-29 |
2002-02-05 |
Kaneka Corporation |
Processes for the preparation of threo-1,2-epoxy-3-amino-4-phenylbutane derivatives
|
|
CA2368023A1
(en)
*
|
1999-03-22 |
2000-09-28 |
Guixue Yu |
Fused pyridopyridazine inhibitors of cgmp phosphodiesterase
|
|
US6605732B1
(en)
*
|
1999-05-03 |
2003-08-12 |
Aerojet Fine Chemicals Llc |
Clean, high-yield preparation of S,S and R,S amino acid isosteres
|
|
KR100708221B1
(ko)
*
|
1999-08-31 |
2007-04-17 |
아지노모토 가부시키가이샤 |
에폭사이드 결정의 제조방법
|
|
US6399393B1
(en)
*
|
1999-09-21 |
2002-06-04 |
The United States Of America As Represented By The Department Of Energy |
Cryogenic homogenization and sampling of heterogeneous multi-phase feedstock
|
|
US6414002B1
(en)
*
|
1999-09-22 |
2002-07-02 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
|
|
US6254888B1
(en)
*
|
2000-01-28 |
2001-07-03 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Method for coating pharmaceutical dosage forms
|
|
US6395767B2
(en)
*
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
|
CZ20011726A3
(cs)
*
|
2000-05-26 |
2002-02-13 |
Pfizer Products Inc. |
Způsob reakční krystalizace, který umoľňuje řídit velikost částic
|
|
JP3843255B2
(ja)
*
|
2000-08-16 |
2006-11-08 |
ブリストル−マイヤーズ スクイブ カンパニー |
置換オキソブタンの立体選択的還元
|
|
IL145106A0
(en)
*
|
2000-08-30 |
2002-06-30 |
Pfizer Prod Inc |
Intermittent administration of a geowth hormone secretagogue
|
|
US6670344B2
(en)
*
|
2000-09-14 |
2003-12-30 |
Bristol-Myers Squibb Company |
Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
|
|
KR20020046948A
(ko)
*
|
2000-12-12 |
2002-06-21 |
에가시라 구니오 |
에폭사이드 결정의 제조방법
|
|
HRP20040181A2
(en)
*
|
2001-08-31 |
2004-08-31 |
Bristol Myers Squibb Co |
Use of atazanavir in hiv therapy
|
|
ATE550375T1
(de)
*
|
2001-09-04 |
2012-04-15 |
Dow Global Technologies Llc |
Wässeriger luftschaum
|
|
NZ533057A
(en)
*
|
2001-10-26 |
2005-11-25 |
Angeletti P Ist Richerche Bio |
N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
|
|
US7384734B2
(en)
*
|
2002-02-15 |
2008-06-10 |
Monogram Biosciences, Inc. |
Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
|
|
KR100456833B1
(ko)
*
|
2002-08-01 |
2004-11-10 |
주식회사 대웅 |
아목시실린 및 클라불라네이트를 함유하는 유핵정
|
|
US20050148523A1
(en)
*
|
2003-12-15 |
2005-07-07 |
Colonno Richard J. |
Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
|
|
TW200534879A
(en)
*
|
2004-03-25 |
2005-11-01 |
Bristol Myers Squibb Co |
Coated tablet formulation and method
|
|
US20050256314A1
(en)
*
|
2004-05-04 |
2005-11-17 |
Soojin Kim |
Process employing controlled crystallization in forming crystals of a pharmaceutical
|
|
US7829720B2
(en)
*
|
2004-05-04 |
2010-11-09 |
Bristol-Myers Squibb Company |
Process for preparing atazanavir bisulfate and novel forms
|
|
US20050288343A1
(en)
*
|
2004-05-19 |
2005-12-29 |
Andrew Rusowicz |
Process of preparing substituted carbamates and intermediates thereof
|
|
TWI354569B
(en)
*
|
2004-05-28 |
2011-12-21 |
Bristol Myers Squibb Co |
Coated tablet formulation and method
|
|
US7582468B2
(en)
*
|
2005-05-25 |
2009-09-01 |
Bristol-Myers Squibb Company |
Process for preparing (2R,3S)-1,2-epoxy-3-(protected)amino-4-substituted butane and intermediates thereof
|
|
WO2007013047A2
(en)
*
|
2005-07-29 |
2007-02-01 |
Ranbaxy Laboratories Limited |
Water-dispersible anti-retroviral pharmaceutical compositions
|